AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 783197
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no ouabain administration)
Trial: 21775883
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (burn wound debridement/topical antiseptic therapy) without ESWT
Trial: 20329656
Drug: Formoterol HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol HFA formulation at 12 microg
Trial: 20329656
Drug: Formoterol HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol HFA formulation at 24 microg
Trial: 20329656
Drug: Reference formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formoterol HFA preparation
Trial: 17426090
Drug: rhIGF-I/rhIGFBP-3 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-I/rhIGFBP-3 (1 mg/kg.d)
Trial: 17426090
Drug: rhIGF-I/rhIGFBP-3 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-I/rhIGFBP-3 (2 mg/kg.d)
Trial: 17426090
Drug: rhIGF-I/rhIGFBP-3 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-I/rhIGFBP-3 (1 mg/kg.d) and (2 mg/kg.d)
Trial: 17426090
Drug: rhIGF-I/rhIGFBP-3 (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIGF-I/rhIGFBP-3 (highest dose groups)
Trial: 11802044
Drug: 10‐mg single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg single dose of intramuscular injection of dexamethasone (n = 39)
Trial: 11802044
Drug: 10‐mg single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg single dose of oral dexamethasone (n = 42)
Trial: 7667171
Drug: Cyproheptadine HCl
RxNorm normalized name: cyproheptadine HCl
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyproheptadine HCl 4 mg 4 times/day
Trial: 7667171
Drug: Cyproheptadine HCl
RxNorm normalized name: cyproheptadine HCl
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyproheptadine HCl 8 mg 4 times/day
Trial: 2719760
Drug: Magnesium oxide,
RxNorm normalized name: Magnesium Oxide, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium oxide, 400 mg capsules, twice a day for 60 days
Trial: 28851310
Drug: Warfarin (post-diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (post-diagnostic use)
Trial: 28851310
Drug: Other types
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other types of anticoagulants
Trial: 28851310
Drug: Warfarin (pre-diagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (pre-diagnostic use)
Trial: 26316273
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g instant decaffeinated coffee with 100 mg caffeine
Trial: 26316273
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g instant decaffeinated coffee with 100 mg caffeine
Trial: 26316273
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g instant decaffeinated coffee with 100 mg caffeine
Trial: 26316273
Drug: Control (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (400 ml water with 50 g glucose)
Trial: 23147455
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of zonisamide (n = 76)
Trial: 11054200
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of diphenhydramine and 50 mg of ranitidine (active group)
Trial: 11054200
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of diphenhydramine and saline solution (control group)
Trial: 8764816
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 600 mg daily
Trial: 3113295
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (180 microgram) administered 15 minutes prior to exercise
Trial: 3113295
Drug: Cromolyn (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn (20 mg) administered 15 minutes prior to exercise
Trial: 3113295
Drug: Cromolyn (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromolyn (20 mg) administered 4 times/day for 2 or 4 weeks
Trial: 24164537
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine and L-asparaginase (experimental arm)
Trial: 24164537
Drug: Standard-dose cytarabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cytarabine, oral 6-mercaptopurine, and cyclophosphamide (standard arm)
Trial: 23291141
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² plus cisplatin 25 mg/m² d1‐3 and 40 Gy of radiation therapy (Arm A)
Trial: 23291141
Drug: Cisplatin 25
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 25 mg/m² d1‐3 plus fluorouracil 600 mg/m² d1 ∼ 5 and 40 Gy of radiation therapy (Arm B)
Trial: 18339420
Drug: Extended release
RxNorm normalized name: Tylenol Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release oxybutynin 10 mg
Trial: 18339420
Drug: Phenazopyridine 200
RxNorm normalized name: phenazopyridine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenazopyridine 200 mg
Trial: 15634033
Drug: Delavirdine 400mg
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delavirdine 400mg three times daily
Trial: 12711838
Drug: NAC 600
RxNorm normalized name: Acetylcysteine 600 MG Oral Capsule [GNC NAC 600]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC 600 mg/day
Trial: 12711838
Drug: NAC 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC 1,800 mg/day
Trial: 12711838
Drug: NAC 1,800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC 1,800 mg/day (after washout period)
Trial: 12711838
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (control group A)
Trial: 8527619
Drug: roxatidine 150
RxNorm normalized name: roxatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 150 mg in the early evening
Trial: 8527619
Drug: roxatidine 150
RxNorm normalized name: roxatidine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxatidine 150 mg at bedtime
Trial: 2312038
Drug: Ranitidine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine maintenance therapy
Trial: 2312038
Drug: Ranitidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine treatment in patients with severe non-stenosing bulb deformity
Trial: 2312038
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in patients with severe non-stenosing bulb deformity
Trial: 2312038
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in patients with normal or mildly deformed bulb
Trial: 2312038
Drug: Ranitidine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine treatment in patients with normal duodenal bulb morphology
Trial: 19263066
Drug: Pre-operative intravenous
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative intravenous dexamethasone (0.5 mg/kg) combined with glossopharyngeal nerve block (3 ml of 0.5% bupivacaine)
Trial: 19263066
Drug: Pre-operative intravenous
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative intravenous dexamethasone (0.5 mg/kg)
Trial: 19263066
Drug: Glossopharyngeal nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glossopharyngeal nerve block (3 ml of 0.5% bupivacaine)
Trial: 11772265
Drug: New antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antifungal agents (terbinafine, itraconazole, fluconazole)
Trial: 7944842
Drug: Pneumococcal vaccine
RxNorm normalized name: PNEUMOCOCCAL VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal vaccine (first or second intramuscular dose)
Trial: 7944842
Drug: Pneumococcal vaccine
RxNorm normalized name: PNEUMOCOCCAL VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal vaccine (revaccination)
Trial: 3130253
Drug: Vigabatrin (1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (1-3 g/day, stratified according to body weight)
Trial: 17010732
Drug: Screening arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Screening arm (prostate-specific antigen testing, digital rectal examination, transrectal ultrasonography, sextant biopsies)
Trial: 12728489
Drug: Premedicated with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedicated with oral midazolam 0.5 mg.kg‐1 (group A (+); n = 19)
Trial: 31372099
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy and visceral manipulation
Trial: 31372099
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy and placebo visceral manipulation
Trial: 29967197
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose edoxaban regimen (60 mg QD)
Trial: 29967197
Drug: Dose-reduced higher
RxNorm normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-reduced higher dose edoxaban regimen (30 mg QD)
Trial: 29967197
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose edoxaban regimen (30 mg QD)
Trial: 29967197
Drug: Dose-reduced lower
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-reduced lower dose edoxaban regimen (15 mg QD)
Trial: 22219221
Drug: GSK598809 (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 (175 mg single oral dose)
Trial: 22219221
Drug: GSK598809 (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK598809 (175 mg single oral dose) + Alcohol infusion
Trial: 15185803
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B Mickey Mouse powered toothbrush
Trial: 15185803
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush (Oral‐B Rugrats 20)
Trial: 12474069
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (500 mg Ca(2+))
Trial: 2674028
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg xipamide + 30 mg triamterene (A)
Trial: 2674028
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg hydrochlorothiazide + 50 mg triamterene (B)
Trial: 11097613
Drug: 5‐fluorouracil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (50 mg/ml for 5 minutes)
Trial: 11097613
Drug: mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mitomycin C (0.4 mg/ml for 2 minutes)
Trial: 1561975
Drug: Pacing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacing group (VVI or DDD pacemaker implant)
Trial: 1561975
Drug: Nonpacing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpacing group (no therapy)
Trial: 3929304
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg metergoline (MET)
Trial: 3929304
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg diazepam (DZ)
Trial: 29684147
Drug: Longer infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer infusions of Meropenem
Trial: 26041481
Drug: Epidermal growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal growth factor (EGF) ointment
Trial: 21516742
Drug: Intravenous alpha-lipoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous alpha-lipoic acid (600 mg/day)
Trial: 15630501
Drug: Erythropoietin (Epo)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo) therapy during the first weeks of life
Trial: 15630501
Drug: Erythropoietin (Epo)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (Epo) therapy
Trial: 15630501
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Epo therapy)
Trial: 2138172
Drug: 12% ammonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% ammonium lactate lotion (Lac‐Hydrin) applied twice daily for 16 weeks
Trial: 23551983
Drug: Intravenous propofol/midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propofol/midazolam
Trial: 12774016
Drug: 500 ng/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ng/kg IL-12 subcutaneously twice weekly for 12 weeks
Trial: 12774016
Drug: IL-12 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-12 therapy
Trial: 11200372
Drug: Enterococcus faecium
RxNorm normalized name: Enterococcus faecium
DrugBank: Enterococcus faecium (DB14225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enterococcus faecium probiotic (150 ml daily, 4.5 x 10^9 to 7.5 x 10^9 CFU E. faecium for 10 days)
Trial: 11200372
Drug: Vancomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (125 mg orally q.i.d. for 10 days)
Trial: 9357377
Drug: Albuterol by
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol by Ventolin metered-dose inhaler (2 puffs, 90 micrograms/puff)
Trial: 9357377
Drug: Albuterol sulfate
RxNorm normalized name: Albuterol Sulfate
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol sulfate powder (Rotacaps) by dry powder inhaler (2 inhalations, 100 micrograms/puff)
Trial: 9357377
Drug: Lactose powder
RxNorm normalized name: Lactose Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose powder by dry powder inhaler (2 inhalations, 12.5 mg/inhalation)
Trial: 2862995
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with low‐dose continuous prednisone (7.5 mg daily)
Trial: 2862995
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy without prednisone
Trial: 29126203
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg daily) with radiation therapy and concurrent/adjuvant temozolomide
Trial: 29126203
Drug: Control (radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (radiation therapy with concurrent and adjuvant temozolomide without everolimus)
Trial: 26714774
Drug: n‐3FA lovaza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3FA lovaza 4 g
Trial: 26714774
Drug: raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raloxifene 60 mg
Trial: 26714774
Drug: raloxifene 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raloxifene 30 mg
Trial: 26714774
Drug: lovaza 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovaza 4 g plus raloxifene 30 mg
Trial: 24661672
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy (RT)
Trial: 15885299
Drug: Peto group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peto group sequential stopping method
Trial: 14512132
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate monohydrate 50-microg nasal spray
Trial: 14512132
Drug: Fexofenadine hydrochloride
RxNorm normalized name: Fexofenadine Hydrochloride
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine hydrochloride 180-mg tablets
Trial: 14512132
Drug: Placebo topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical solution
Trial: 8901655
Drug: High-dose Integrelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Integrelin (90 micrograms/kg bolus followed by 1.0 microgram.kg‐1.min‐1 continuous infusion)
Trial: 8901655
Drug: Low-dose Integrelin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Integrelin (45 micrograms/kg bolus followed by 0.5 microgram.kg‐1.min‐1 continuous infusion)
Trial: 1809429
Drug: p.r.n. intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.r.n. intravenous morphine
Trial: 6882604
Drug: Atenolol (during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (during treatment)
Trial: 31444917
Drug: Poloxamer-based thermo-sensitive
RxNorm normalized name: Poloxamer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poloxamer-based thermo-sensitive sol-gel instillation
Trial: 24841163
Drug: Ciclesonide (CIC)
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide (CIC) 320 μg once daily
Trial: 24841163
Drug: Budesonide (BUD)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (BUD) 200 μg two inhalations twice daily
Trial: 22007656
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb exercises followed by manual therapy (MT)
Trial: 17312210
Drug: Sugammadex, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex, 4 mg/kg IV (n = 20)
Trial: 17312210
Drug: Edrophonium, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium, 1 mg/kg IV and atropine, 10 microg/kg IV (n = 20)
Trial: 15802292
Drug: N(G)-monomethyl-L-arginine (L-NMMA)
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N(G)-monomethyl-L-arginine (L-NMMA) infusion
Trial: 9852985
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine (Oka strain) at 3200 pfu/dose
Trial: 9852985
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine (Oka strain) at 8500 pfu/dose
Trial: 9852985
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated VZV vaccine (Oka strain) at 41,650 pfu/dose
Trial: 9852985
Drug: Control pneumococcal
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control pneumococcal polysaccharide vaccine
Trial: 3141301
Drug: Enoxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin (400 mg tablet)
Trial: 3141301
Drug: Ceftriaxone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (250 mg injection)
Trial: 21676232
Drug: Conventional Radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Radiotherapy in 28 fractions to a dose of 50.4 Gy and consecutive boost in 8 fractions to a total dose of 66.4 Gy
Trial: 16525138
Drug: Entecavir 0.5
RxNorm normalized name: entecavir 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5 mg once daily for a minimum of 52 weeks
Trial: 16525138
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg once daily for a minimum of 52 weeks
Trial: 14633754
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ropivacaine 0.2% 5 ml h(‐1) for 55 h after infiltration with ropivacaine 0.5% 40 ml.
Trial: 14633754
Drug: Systemic analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic analgesia with continuous i.v. infusion of morphine plus ketorolac for 24 h followed by saline infusion for 55 h.
Trial: 11602412
Drug: Computer-aided dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-aided dosing
Trial: 9580382
Drug: Aripiprazole (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (8 weeks of open‐label treatment)
Trial: 26656642
Drug: Donepezil (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (first dose)
Trial: 23490304
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Compliance Enhancement Therapy (BBCET)
Trial: 19537033
Drug: Ulinastatin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (4 x 10^6 U in 100 ml normal saline infused intravenously for 30 min since skin incision, with additional 2 x 10^6 U infused at a rate of 4-6 x 10^4 U x h(-1) until chest closure)